

"2. Dextropropoxyphene has a currently accepted medical use in treatment in the United States.

"3. Abuse of dextropropoxyphene may lead to limited physical dependence or psychological dependence relative to the drugs or other substances in Schedule III."

Those conclusions were, in turn, based on advice that DEA had received from the Department of HEW, from the FDA, and from the Controlled Substances Advisory Committee. The full text of the HEW recommendation is included at the end of Tab I of the Blue Book.

A decision to place propoxyphene products in Schedule II would require findings that propoxyphene is a drug:

"(1) that has a 'high potential for abuse,'

"(2) that has 'a currently accepted medical use in treatment in the United States, or a currently accepted medical use with severe restrictions,' and

"(3) for which abuse may lead to 'severe psychological or physical dependence.'"

For propoxyphene products to be placed in Schedule II, conclusions substantially different from those made previously by DEA, HEW, FDA, and the Controlled Substances Advisory Committee would be necessary. We believe that no evidence has been presented that would invalidate these earlier conclusions.